Loading...
Maraviroc is the first CCR5 inhibitor approved for HIV treatment. As previously reported, FDA approval was based primarily on 24-week results from the MOTIVATE studies, which involved more than 1000 highly treatment-experienced patients infected with CCR5-tropic virus (ACC Aug 10 2007). At the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, investigators reported subgroup analyses from the MOTIVATE studies and also provided data from the MERIT study about the use of maraviroc in treatment-naive patients.
In a pooled 24-week analysis of the two MOTIVATE studies, Gulick and colleagues confirmed results previously reported from the two individual studies: When combined with an optimized background regime…